Horton, Rebecca H;
Saade, Dimah;
Markati, Theodora;
Harriss, Elinor;
Bonnemann, Carsten G;
Muntoni, Francesco;
Servais, Laurent;
(2022)
A systematic review of adeno-associated virus gene therapies in neurology: the need for consistent safety monitoring of a promising treatment.
Journal of Neurology, Neurosurgery & Psychiatry
10.1136/jnnp-2022-329431.
(In press).
Preview |
Text
Muntoni_AAV Gene Therapy Final for Open Access (without tables).pdf - Other Download (387kB) | Preview |
Preview |
Text
Muntoni_Tables for SRAAV 37.pdf - Other Download (7MB) | Preview |
Abstract
Adeno-associated virus (AAV) gene therapies are generating much excitement in the rare disease field, particularly for previously untreatable neurological conditions. Efficacy has been claimed for several gene therapy products and the number of trials is rapidly increasing. However, reports of severe treatment-related adverse reactions are emerging, including death. There is still insufficient knowledge about their aetiology, prevention and treatment. We therefore undertook to systematically review publicly available data on AAV gene therapies in order to collate existing information on both safety and efficacy. Here, we review emerging efficacy reports of these novel therapies, many of which show promise. We also collate an increasing number of adverse reactions. Overwhelmingly, these results make a case for unified reporting of adverse events. This is likely to be critical for improving the safety of these promising treatments.
Type: | Article |
---|---|
Title: | A systematic review of adeno-associated virus gene therapies in neurology: the need for consistent safety monitoring of a promising treatment |
Location: | England |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.1136/jnnp-2022-329431 |
Publisher version: | http://dx.doi.org/10.1136/jnnp-2022-329431 |
Language: | English |
Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
Keywords: | Science & Technology, Life Sciences & Biomedicine, Clinical Neurology, Psychiatry, Surgery, Neurosciences & Neurology, SPINAL MUSCULAR-ATROPHY, ACID DECARBOXYLASE DEFICIENCY, 1/2 CLINICAL-TRIAL, ONASEMNOGENE ABEPARVOVEC, OPEN-LABEL, IMMUNE-RESPONSES, REPLACEMENT THERAPY, SINGLE-ARM, FACTOR-IX, PHASE-I |
UCL classification: | UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology |
URI: | https://discovery.ucl.ac.uk/id/eprint/10157751 |
Archive Staff Only
![]() |
View Item |